4th mRNA-Based Therapeutics Summit

2023 saw the Nobel Prize awarded to mRNA technology, reinvigorating the field and spurring a new wave of candidates entering the clinic. The industry has made tremendous strides in applying mRNA technology beyond COVID-19, and as mRNA unlocks the rare, infectious and oncological spaces, the 4th mRNA-Based Therapeutics Summit maintains its position as the world's most comprehensive, end-to-end industry-dedicated conference, bringing you exclusive scientific and strategic insights from the biggest players across indications and modalities.

Join 400+ mRNA experts and enthusiasts to hear unseen data from 65+ world-class speakers from the likes of CureVac, Moderna, BioNTech and Sanofi, and gain exclusive regulatory insights from the FDA and EMA.

Personalize your experience and select which sessions best apply to you, by navigating through 4 tracks of content catering to discovery, translation, clinical development and chemistry, manufacturing and controls. Join interactive roundtables and a CEOs' Panel Discussion, choose from the Regulatory Affairs Strategy or Next Generation mRNA Delivery focus days, and forge meaningful connections in the dedicated networking sessions.


URLs:
Website: https://go.evvnt.com/2261640-0?pid=10018
Tickets: https://go.evvnt.com/2261640-2?pid=10018
Brochure: https://go.evvnt.com/2261640-3?pid=10018

Prices:
Conference + Delivery Focus Day - Drug Developer Pricing: USD 5296.00,
Conference + Regulatory Focus Day - Drug Developer Pricing: USD 5296.00,
Conference Only - Drug Developer Pricing: USD 3199.00,
Conference + Delivery Focus Day - Solution Provider Pricing: USD 6396.00,
Conference + Regulatory Focus Day - Solution Provider Pricing: USD 6396.00,
Conference Only - Solution Provider Pricing: USD 3999.00,
Conference + Delivery Focus Day - Academic Pricing: USD 4596.00,
Conference + Regulatory Focus Day - Academic Pricing: USD 4596.00,
Conference Only - Academic Pricing: USD 1899.00

Speakers: Ajan Reginald, Chief Executive Officer, Roquefort Therapeutics, Alexander Zehnder, Chief Executive Officer, CureVacSE, Andrew Allen, Chief Executive Officer, Gritstone bio, Inc., Andy Geall, Chief Executive Officer, Replicate Biosciences, Anne De Groot, Chief Executive Officer, EpiVax Therapeutics, Chris Jewell, Chief Scientific Officer, Cartesian Therapeutics, Emma Wang, Chief Technology Officer, YolTech Therapeutics, Giles Besin, Chief Scientific Officer, Orbital Therapeutics, Giuseppe Ciaramella, President, Chief Executive Officer, Beam Therapeutics, Orbital Therapeutics, Guilhem Richard, Chief Scientific and Technology Officer, Epivax Therapeutics, Guillaume Pfefer, Chief Executive Officer, Sail Biomedicines, Hang Yuan, Co-Founder and Chief Technology Officer, Innovac Therapeutics, Joe Payne, Chief Executive Officer, Arcturus Therapeutics, Matt Angel, Chief Executive Officer, Factor Bioscience , Matthew Hawryluk, Chief Business Officer, Gritstone bio, Inc., Nathaniel Wang, Chief Executive Officer, Replicate Bioscience, Nicholas Valiante, Co-Founder and Chief Scientific Officer, Innovac Therapeutics, Peter Berglund, Chief Scientific Officer, HDT Bio, Randall Moreadith, President and Chief Executive Officer, Serina Therapeutics, Robert Mabry, Chief Scientific Officer, Orna Therapeutics, Sam Deutsch, Chief Scientific Officer, Nutcracker Therapeutics, Sophia Lugo, Chief Executive Officer, Radar Therapeutics, Alisa Zhilin Roth, Senior Scientist, In vitro and Mechanism, Sanofi, Allen Horhota, Head of Platform, Orna Therapeutics, Amit Srivastava, Vice President, RNA Therapeutics Portfolio Enhancement, Orbital Therapeutics, Andy Ferguson, Vice President, Clinical Science, Gritstone Bio , Annette Bak, Head of Drug Delivery AstraZeneca, Beata Chertok, Team Lead, Delivery of Intracellular Biologics, AstraZeneca, Carla Vinals, Vice President, Global Regulatory Product Strategy, Moderna, Cheng Chang, Associate Director, RNA Platform, CSL, Daniel Quevedo, Associate Director, Metis Therapeutics, Emily English, Vice President, Quality, Cartesian Therapeutics, Francis Poulin, Vice President, Analytical Sciences, Sail Biomedicines, Gad Berdugo, Managing Partner; Strategic Advisor, Explorium Capital LLC; Nutcracker Therapeutics, Hanae Toyonoga, Discovery Accelerator, Astellas Pharma, Jesse Erasmus, Director, Virology, HDT Bio, Jon Shanter, Director, RNA Vaccine and Advanced Biotechnologies Process Research and Development, Merck and Co, Joshua Di Napoli, Global Project Head, mRNA Platform Development, Sanofi, Kumar Namdev, Global Head, CMC Product development and industrialization, Sanofi, Kyle Holen, Head of Development, Oncology and Therapeutics, Moderna, Laura Babel, Associate Director, Formulation and Assay Development, BioNTech, Lei Cheng, Associate Director, mRNA Therapy, Astellas Pharma, Manfred Kraus, Vice-President, Head of R and D Therapeutics, Kernal Biologics, Marco Cavaleri, Head of Biological Health Threats and Vaccines Strategy, European Medicines Agency, Michael Rosenzweig, EVP, Portfolio Strategy and Product Development, Capstan Therapeutics, Nazia Noor, Vice President, Global Regulatory Affairs CMC, BioNTech , Nitisha Pyndiah, Global Regulatory Lead, GlaxoSmithKline Plc, Peter Marks, Director, US Food and Drug Administration (FDA), Priyanka Acharya, Senior Scientist, Merck and Co, Rachel Groppo, Director, Lead Self-Amplifying RNA Team, Johnson and Johnson Innovative Medicine, Till Schoofs, Director, Clinical Development, Infectious Diseases, Moderna, Xiangrong Song, Co-Founder and General Manager, WestGene Biopharma, Dimki Patel, CMC Program Leader, CEPI, Duccio Medini, R3 Program Director, Wellcome Leap, Jessica Rouge, Associate Professor and Paul Krenicki Chair of Chemistry, University of Connecticut , Lyudmila Kovalchuke, Project Manager, VIB-UGent, Rachel Sari Riley, Associate Professor, Rowan University, Richard Braatz, Director, Centre of Continuous mRNA Manufacturing, MIT, Jamison Grailer, Senior Research Scientist, Promega, Jing Zhu, VP, mRNA Technology, ReciBioPharm, John Patton, Head of Inhalation, Scientific Advisory Board, Kindeva Drug Delivery, May Guo, Chief Commercial Officer, Areterna, Peter Chu, Chief Executive Officer, Eclipse Bio, Scott Alderucci, Director, Process Development Science, Curia, Syed Reza, Scientific and Sales Consultant, NOF, Tomas Kostelec, Product Manager, pDNA/RNA, Sartorius BIA Separations